Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
Status:
Completed
Trial end date:
2019-06-20
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine if single-bolus recombinant nonimmunogenic
staphylokinase is effective and save thrombolytic agent in patients with ischemic stroke in
comparison to alteplase.